Castle Biosciences vs Schrodinger
Castle Biosciences is the larger business, with $344m of revenue in fiscal 2025 against $256m for Schrodinger (1.3 times as much). Schrodinger grew faster (23.3% against 3.7%). Castle Biosciences kept more of each dollar of sales as profit: a net margin of -7.0% against -40.4%. Schrodinger carries less debt relative to equity (0.0% against 2.2%).
| Latest fiscal year | Castle BiosciencesCSTL, 2025 | SchrodingerSDGR, 2025 |
|---|---|---|
| Revenue | $344m | $256m |
| Revenue growth | 3.7% | 23.3% |
| Net income | −$24.2m | −$103m |
| Operating margin | -12.4% | -65.2% |
| Net margin | -7.0% | -40.4% |
| Return on equity | -5.2% | -26.3% |
| Free cash flow | $28.3m | $12.5m |
| Cash | $117m | $231m |
| Total debt | $10.2m | $0 |
| Debt to equity | 2.2% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 883 | 850 |
| Market value | $1.07bn | $2.05bn |
| Price vs our value range | — | — |
| Moat score | 32 (Weak) | 28 (Weak) |
| Insider trades, 12 months | 0 buys, 170 sales | 0 buys, 20 sales |